A high-throughput liposome substrate assay with automated lipid extraction process for PI 3-kinase

Journal of Biomolecular Screening

Volumn 13, Issue 9, 2008, Pages 906-911

  Lingaraj, Trupti ^a   Donovan, John ^a   Li, Zhi ^a   Li, Ping ^a   Doucette, Amanda ^a   Harrison, Sean ^a   Ecsedy, Jeffrey A ^a   Dang, Lenny ^a   Zhang, Wenhai ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

High throughput screening; Lipid extraction; Liposome; PI 3 kinase p110

Indexed keywords

LIPID; LIPOSOME; PHOSPHATIDYLINOSITOL 3 KINASE;

ARTICLE; AUTOMATION; ENZYME ANALYSIS; ENZYME ASSAY; ENZYME INHIBITION; ENZYME ISOLATION; ENZYME MECHANISM; ENZYME SUBSTRATE; HIGH THROUGHPUT SCREENING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; THIN LAYER CHROMATOGRAPHY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOSINE TRIPHOSPHATE; AUTOMATION; BIOCHEMISTRY; CHROMATOGRAPHY, THIN LAYER; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; LIPIDS; LIPOSOMES; NEOPLASMS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY; TIME FACTORS;

EID: 53649086325     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057108324498     Document Type: Article

References (15)

1. Cantley LC: The phosphoinositide 3-kinase pathway. Science 2002 ; 296: 1655-1657.
2. Wymann MP, Zvelebil M., Laffargue M.: Phosphoinositide 3-kinase signaling: which way to target ? Trends Biochem Sci 2003 ; 24: 366-376.
3. Hennessy BT, Smith DL, Ram PT, Lu Y., Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005 ; 4: 988-1004.
4. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S.,, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004 ; 304: 554.
5. Kang S., Bader A., Vogt P.: Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. PNAS 2005 ; 102: 802-807.
6. Angelo P., Anita M., Amalia A., Stefania T.: Phosphatidylinositol 3-kinase in breast cancer: where from here ? Clin Cancer Res 2007 ; 13: 5988-5990.
7. Serunian LA, Auger KR, Cantley LC: Identification and quantification of polyphosphoinositides produced in response to platelet-derived growth factor stimulation. Methods Enzymol 1991 ; 198: 78-87.
8. Barnett SF, Ledder LM, Stirdivant SM, Ahern J., Conroy RR, Heimbrook DC: Interfacial catalysis by phosphoinositide 3′-hydroxykinase. Biochemistry 1995 ; 34: 14254-14262.
9. Gary A., Olsson H., Batty IH, Priganica L., Downes PC: Nonradioactive methods for the assay of phosphoinositide 3-kinaes and phosphoinositide phosphatases and selective detection of signaling lipids in cell and tissue extracts. Anal Biochem 2003 ; 313: 234-245.
10. Hayakawa M., Kaizawa H., Moritomoa H., Koizumi T., Ohishi T., Okada M.,, et al. Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI 3-kinase p110α inhibitors. Bioorg Med Chem 2006 ; 14: 6847-6858.
11. Fuchikami K., Togame H., Sagara A., Satoh T., Gantner F., Bacon KB,, et al. A versatile high-throughput screen for inhibitors of lipid kinase activity: development of an immobilized phospholipid plate assay for phosphoinositide 3-kinase gamma. J Biomol Screen 2002 ; 7: 441-450.
12. Knight ZA, Feldman ME, Balla A., Balla T., Shokat KM: A membrane capture assay for lipid kinase activity. Nat Protoc 2007 ; 2: 2459-2466.
13. Klink TA, Kleman-Leyer KM, Kopp A., Westermeyer TA, Lowery RG: Evaluating PI3 kinase isoforms using Transcreener™ ADP assays. J Biomol Screen 2008 ; 13: 476-485.
14. Beeton CA, Chance EM, Foukas LC, Shepherd PR: Comparison of the kinase properties of the lipid- and protein-kinase activities of the p110α and p110β catalytic subunits of class-IA phosphoinositide 3-kinases. Biochem J 2000 ; 350: 353-359.
15. Carson JD, Van Aller G., Lehr R., Sinnamon RH, Kirkpatrick RB, Auger KR,, et al. Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase. Biochem J 2008 ; 409: 519-524.